Oppenheimer analyst Timothy Horan downgrades QualTek Services (NASDAQ:QTEK) from Outperform to Perform.
The Science Times Publishes Article About Jaguar Health’s Focus On Developing Crofelemer For Two Rare Disease Indications
Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion disease in the EU and Middle East/North Africa
